Loading
Life sciences · Journal article
Frontiers in Endocrinology · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Insulin resistance(IR) is a key driver of cardiorenal-metabolic diseases. The Triglyceride Glucose-Body Mass Index (TyG-BMI), a composite marker of lipid-glucose metabolism and overall adiposity, has gained traction as a predictive tool. Its clinical application, however, is complicated by non-linear and sometimes paradoxical associations with clinical outcomes, a phenomenon reminiscent of the”obesity paradox”. This review critically evaluates the performance of TyG-BMI across the spectrum of kidney disease, aiming to reconcile these divergent findings through a metabolic-endocrine framework. Methods We performed a narrative synthesis of observational studies and secondary analyses of large-scale public databases such as National Health and Nutrition Examination Survey(NHANES), China Health and Retirement Longitudinal Study(CHARLS), UK Biobank, Medical Information Mart for Intensive Care IV(MIMIC-IV), identified through PubMed and Google Scholar, to evaluate the association of TyG-BMI with the incidence, progression, and prognosis of acute kidney injury (AKI), diabetic kidney disease (DKD), chronic kidney disease (CKD), and Cardiovascular-Kidney-Metabolic syndrome(CKM). Results TyG-BMI shows significant, context-dependent predictive value. In early-stage or metabolically heterogeneous populations, elevated TyG-BMI consistently predicts higher disease risk. Conversely, in advanced stages (e.g., end-stage renal disease, stage 4 CKM), the association frequently becomes U-shaped, with low TyG-BMI paradoxically linked to excess mortality. This reflects its dual nature: the TyG component captures ‘metabolic toxicity’, while BMI proxies ‘nutritional reserve’. Thus, the ‘obesity paradox’ may represent a metabolic phenotype spectrum—from metabolically healthy obesity (MHO) to metabolically unhealthy lean (MUL)—that the combination of its TyG and BMI components helps differentiate. For disease incidence prediction, TyG-BMI is often outperformed by indices of central obesity (e.g., Triglyceride-Glucose-Waist Circumference Index(TyG-WC), Triglyceride-Glucose–Waist-to-Height Ratio(TyG-WHtR); for mortality in advanced illness, the standalone TyG index may be superior. Conclusion TyG-BMI is a valuable tool for metabolic phenotyping and risk stratification in kidney disease, with its paradoxical associations highlighting the complex interplay between metabolic health and nutritional reserve. Future research must establish context-specific clinical thresholds. TyG-BMI is preferentially useful in settings where waist circumference is unavailable, in early CKD screening, and in select type 2 diabetes mellitus (T2DM) subgroups. In advanced CKD, dialysis, critical illness, and CKM stage 4, alternative indices such as TyG index, TyG-WC, or TyG-WHtR should be prioritized due to the confounding effects of fluid overload and catabolic state.